Literature DB >> 16950596

Effects of steatosis on drug-metabolizing capability of primary human hepatocytes.

M T Donato1, N Jiménez, A Serralta, J Mir, J V Castell, M J Gómez-Lechón.   

Abstract

The suitability of liver grafts discarded for transplantation because of macrosteatosis for preparing human hepatocyte cultures for in vitro drug metabolism studies has been examined. Lower cell viability and yield of isolation procedure were obtained from fatty livers (>40% steatosis) with respect to normal tissue. Significant reductions in 7-ethoxycoumarin O-deethylation (ECOD) and testosterone oxidations were found in hepatocytes prepared from steatotic livers. The potential impact of lipid accumulation on P450 enzymes was studied in vitro by incubation of cultured hepatocytes with long chain free fatty acids (FFA). Treatment of cells with 0.25-3mM FFA induced dose-dependent accumulation of lipids in the cytosol. Decreased ECOD and testosterone oxidation were found after 14h of exposure to 1mM or 2mM FFA (about 60-70% and 30-60% of control, respectively). The effects of fat-overloading on individual P450s were analyzed both at activity and mRNA level. CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities were reduced after hepatocyte incubation with 1mM (to 45-65% of control) or 2mM (to 20-50%) FFA for 14h. Reductions in P450 transcripts were also found in hepatocytes treated with 1mM FFA. Our findings showed a general down-regulation of P450s involved in drug metabolism in fat-overloaded hepatocytes. The results suggest that, despite their reduced P450 function, human hepatocytes obtained from donors with steatosis are metabolically competent and could be used for drug metabolism studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950596     DOI: 10.1016/j.tiv.2006.07.008

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  18 in total

Review 1.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 3.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 4.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

Review 5.  Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism.

Authors:  Jie Gao; Wen Xie
Journal:  Drug Metab Dispos       Date:  2010-08-24       Impact factor: 3.922

6.  Suppression of the pregnane X receptor during endoplasmic reticulum stress is achieved by down-regulating hepatocyte nuclear factor-4α and up-regulating liver-enriched inhibitory protein.

Authors:  Thaveechai Vachirayonsti; Karen W Ho; Dongfang Yang; Bingfang Yan
Journal:  Toxicol Sci       Date:  2015-01-22       Impact factor: 4.849

7.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.

Authors:  James P Hardwick; Douglas Osei-Hyiaman; Homer Wiland; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  PPAR Res       Date:  2010-03-16       Impact factor: 4.964

8.  Induction of CYP2E1 in non-alcoholic fatty liver diseases.

Authors:  Ghanim Aljomah; Susan S Baker; Wensheng Liu; Rafal Kozielski; Janet Oluwole; Benita Lupu; Robert D Baker; Lixin Zhu
Journal:  Exp Mol Pathol       Date:  2015-11-10       Impact factor: 3.362

Review 9.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

Review 10.  The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies.

Authors:  Meysam Zarezadeh; Ahmad Saedisomeolia; Mahoor Shekarabi; Masoud Khorshidi; Mohammad Reza Emami; Daniel J Müller
Journal:  Eur J Nutr       Date:  2020-11-03       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.